Brain

Executive Wellness Retreats: Grey Matters International Announces Expansion of Neuroscience-Based Programs

Discover a neuroscience-based path to better mental health and executive well-being with Grey Matters International. Their personalized retreats combine brain…

2 months ago

JOURTHON® Launches Brain Health Softgel

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Memory lapses, poor concentration, and mental fatigue are no longer just signs…

2 months ago

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9,…

2 months ago

Apollo Biowellness, Inc., Merger Update

North Bergen, New Jersey--(Newsfile Corp. - October 9, 2025) -  Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to…

2 months ago

Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions

TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader…

2 months ago

Can Neuroimaging Save Psychedelic Drug Development? Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how neuroimaging technologies like PET, fMRI and multimodal approaches provide objective insights into brain mechanisms…

2 months ago

Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…

2 months ago

Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…

2 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the…

2 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc.…

2 months ago